NCT00522457View on ClinicalTrials.gov

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Metastatic Breast CancerAdvanced Breast Cancer
Interventions
DRUG

ertumaxomab

Ertumaxomab will be intravenously administered to see if it can increase the patient's objective response rate.

Trial Locations (5)

Unknown

Minneapolis

Lebanon

New York

Ottawa

Montreal

Sponsors

Lead Sponsor

Neovii Biotech
All Listed Sponsors
collaborator

Fresenius Biotech North America

INDUSTRY

lead

Neovii Biotech

INDUSTRY

NCT00522457 - Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy | Biotech Hunter | Biotech Hunter